This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Gentris Corporation Announces Changes To Board Of Directors

Stock quotes in this article: TZYM

Related Links:  

Quotes:

"As Gentris enters its second decade, the Company is fortunate to have experienced executives like Dr. David Drutz and Tim Gupton serving on the Board of Directors," said Rick Williams, CEO of Gentris Corporation. "Dr. Drutz and Mr. Gupton have been involved in many facets of the biopharma industry.  They understand how to guide a senior management team and its advisors to create scientific innovation and generate high-growth commercial results."

"Pharmacogenomics is directed to understanding how drugs interact with our genetic makeup," said Dr. David Drutz, chair of the Gentris board of directors.  "As such, pharmacogenomics enables therapeutic agents to be directed toward those individuals most likely to have a favorable clinical response and away from those most likely to suffer adverse effects.  Pharmacogenomics serves as a centerpiece for the future of drug development in the pharmaceutical and biotechnology industries.  I am delighted to be associated in such an important way with a well-established company that is working at the cutting edge in this exciting endeavor."

"As an investor from Research Triangle Ventures," Tim Gupton said, "I've been associated with Gentris since its inception.  Gentris has always been driven by excellent science and quality standards and has been a leader in helping the pharmaceutical industry to use genetic data to differentiate their drug candidates.  With clinical biomarkers becoming an expectation for drug development, I'm confident that Gentris will remain a leader in the rapidly growing field of personalized medicine."

About Gentris Corporation:

Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.  In the past year, Gentris significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.

The Gentris team has collaborated with sponsors to incorporate pharmacogenomics into more than five hundred clinical trials around the world.  Its scientists routinely design complex de novo genomic assays.  The Company's Integrated BioRepository Solutions business unit manages study-site logistics, conduct genomic assessments, and store patient biospecimens.

For additional information, please visit www.gentris.com or call 919.653.5534.

Keywords:

Gentris Corporation, Genomics, Clinical Genomics, Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Individualized Medicine, Biomarkers, Genomic Assays, Genomic Methods, Hepatitis, Oncology, Cancer, Immunology, Biobanking, Biorepository, Biospecimens, Integrated BioRepository Solutions.

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,782.24 -260.66 -1.53%
S&P 500 1,946.93 -25.36 -1.29%
NASDAQ 4,421.1990 -72.1910 -1.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs